Shots:

• The PATRO Children- post marketing surveillance study evaluates biosimilar rhGH (Omnitrope) vs reference rhGH (Genotropin) in 348 children with TS at 130 centers across EU. In this study- 81.6% were rhGH naïve- and 90.2% were prepubertal
• The results demonstrated that the therapy was safe & effective in real-life clinical practice- was generally well tolerated with no unexpected safety signals.
• Mean duration of treatment was 38.5mos.- 48.9% experienced AEs substantial height gains in prepubertal individuals aged 3+ yrs. Additionally- 49.4% of patients discontinued the study

| Ref: Centre for Biosimilar| Image: Reuters